Sagimet Biosciences Inc. financial data

Symbol
SGMT on Nasdaq
Industry
Pharmaceutical Preparations
Location
155 Bovet Rd., Suite 303, San Mateo, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
3-V Biosciences, Inc. (to 2/25/2019)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3.15 %
Return On Equity -23.6 % -205%
Return On Assets -22.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.7M shares +43.5%
Common Stock, Shares, Outstanding 0 shares -100%
Weighted Average Number of Shares Outstanding, Basic 32.1M shares +76.7%
Weighted Average Number of Shares Outstanding, Diluted 32.1M shares +76.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2M USD
Research and Development Expense 29.9M USD +155%
General and Administrative Expense 15.8M USD -5.45%
Operating Income (Loss) -45.7M USD -127%
Net Income (Loss) Attributable to Parent -37.5M USD -39.4%
Earnings Per Share, Basic 68.1 USD/shares -28.6%
Earnings Per Share, Diluted 68.1 USD/shares -28.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77M USD -24.4%
Marketable Securities, Current 75.5M USD
Cash, Cash Equivalents, and Short-term Investments 170M USD
Other Assets, Current 101K USD +31.2%
Assets, Current 157M USD +52.9%
Operating Lease, Right-of-Use Asset 114K USD +4.59%
Assets 175M USD +69.8%
Accounts Payable, Current 1.15M USD -32.3%
Employee-related Liabilities, Current 995K USD +44.4%
Accrued Liabilities, Current 2.82M USD -12.9%
Liabilities, Current 5.65M USD +7.1%
Liabilities 4.09M USD -19%
Accumulated Other Comprehensive Income (Loss), Net of Tax 441K USD
Retained Earnings (Accumulated Deficit) -279M USD -15.5%
Stockholders' Equity Attributable to Parent 171M USD +74.4%
Liabilities and Equity 175M USD +69.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.21M USD +12.4%
Net Cash Provided by (Used in) Financing Activities 105M USD
Net Cash Provided by (Used in) Investing Activities 3M USD -84.5%
Common Stock, Shares Authorized 0 shares -100%
Common Stock, Shares, Issued 0 shares -100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77M USD -24.4%
Deferred Tax Assets, Valuation Allowance 55.1M USD +15.2%
Deferred Tax Assets, Gross 55.2M USD +15.2%
Operating Lease, Liability 65K USD -69.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.1M USD -123%
Lessee, Operating Lease, Liability, to be Paid 66K USD -72.2%
Operating Lease, Liability, Current 116K USD +12.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 66K USD -58%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -96.2%
Deferred Tax Assets, Operating Loss Carryforwards 31.1M USD +8.33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.78M USD +16.3%
Additional Paid in Capital 449M USD +32.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 43K USD -4.44%
Share-based Payment Arrangement, Expense 5.07M USD -16.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%